BioReperia, a privately owned contract research organization (CRO) founded in September 2015, leverages technology developed at a Swedish university to accelerate drug discovery and enhance clinical trials. The company operates primarily in the European market, serving academic institutions and pharmaceutical companies. BioReperia specializes in using well-characterized clonal cultures of tumor cell lines to maximize experimental control and data accuracy. Their services include evaluating drug candidates in novel in vivo systems and testing individual treatments on specific patients. By offering an extensive library of over 4000 human cell lines and various CDX models, BioReperia enables clients to screen a large number of drug combinations, including non-malignant tumor infiltrating cells, to find the best treatment options. The business model revolves around providing specialized research services to its clients, generating revenue through contract-based projects.

Keywords: drug discovery, clinical trials, CRO, in vivo systems, tumor cell lines, CDX models, personalized treatment, pharmaceutical, academic research, European market.